Physician profile
Amanda Rutherford
NPI 1275877474
$597.76
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $195 · 2023: $173 · 2024: $27.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $136.85 | 2022 | |
| Glaxosmithkline, LLC. | $84.14 | 2021-2023 | Shingrix, Bexsero |
| Exact Sciences Corporation | $48.79 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $45.92 | 2023 | |
| Lilly USA, LLC | $44.87 | 2021-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $44.40 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.27 | 2021 | |
| Pfizer INC. | $30.31 | 2022-2023 | |
| Amgen INC. | $28.09 | 2021-2023 | Evenity, Prolia |
| Sk Life Science, INC. | $27.18 | 2024 | |
| Dynavax Technologies Corporation | $24.77 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2022 | |
| Genentech USA, INC. | $13.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Rutherford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.